Zimmer Biomet Holdings, INC 10-Q quarterly reports

Zimmer Biomet Holdings, Inc. announced a 4.8% increase in net sales for the second quarter of 2026, driven by acquisitions, favorable currency, and product demand.

Zimmer Biomet reported a 9.3% increase in Q1 2026 net sales to $2.09 billion, driven by the Paragon 28 acquisition and strong demand for robotic and surgical technologies.

Zimmer Biomet Holdings, Inc. reported a 9.7% increase in net sales for the third quarter of 2025, driven by strategic acquisitions and market growth, despite a decline in net earnings.

Zimmer Biomet Holdings, Inc. reported a 7% increase in net sales for Q2 2025, driven by acquisitions and market growth, but net earnings significantly declined due to acquisition-related costs and higher interest expenses.

Zimmer Biomet's Q1 2025 net sales rose by 1.1% year-over-year, but the company anticipates lower net earnings for the year due to acquisition and integration costs related to Paragon 28.

Zimmer Biomet's Q3 2024 results show a net sales increase of 4.0% year-over-year, despite operational challenges from a new ERP system implementation.

Zimmer Biomet's Q2 2024 results show a net sales increase but a decrease in net earnings for the six-month period, influenced by restructuring costs and other factors.

Zimmer Biomet's first quarter net sales increased by 3.2%, while net earnings declined due to restructuring charges.